Suppr超能文献

无高泌乳素血症的泌乳素分泌型垂体腺瘤的单中心经验:其发病率和临床处理。

A single- center experience of prolactin-producing pituitary adenomas without hyperprolactinemia: Its incidence and clinical management.

机构信息

Department of Neurosurgery, Kohnan Hospital, Sendai, Miyagi, Japan.

Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

出版信息

Clin Neurol Neurosurg. 2020 Nov;198:106123. doi: 10.1016/j.clineuro.2020.106123. Epub 2020 Aug 3.

Abstract

OBJECTIVE

This study clarifies the incidence of prolactin-producing pituitary adenomas without hyperprolactinemia and determines the appropriate treatment strategy for these tumors.

PATIENTS AND METHODS

This retrospective analysis focused on prolactin-producing adenomas without hyperprolactinemia, which were initially treated by surgery as nonfunctioning pituitary adenomas. Among 942 patients with histologically confirmed pituitary adenoma, 114 (12.1 %) patients, consisting of 68 men and 46 women, who had prolactin-producing adenomas without hyperprolactinemia were identified between April 2005 and March 2019.

RESULTS

Of the 114 patients identified, 13 (11.4 %) had prolactin mono-expressions, 18 (15.8 %) had pit-1 lineage hormonal expressions, and 83 (72.8 %) had paradoxical immunoexpression out of the pituitary differentiation lineage, including prolactin. During the follow-up period, 19 patients suffered tumor progression, and 14 required salvage treatment. Of the 19 patients, 11 underwent gamma knife radiosurgery, and none of them experienced further tumor progression. Cabergoline was administered of them to six patients, and one achieved tumor shrinkage. However, the remaining five patients who were treated with cabergoline suffered further tumor progression and required another salvage treatment. Among the patients in the prolactin mono-expression group, one experienced tumor regrowth and underwent gamma knife radiosurgery. In the pit-1 lineage group, two patients experienced tumor regrowth. One had further tumor progression after treatment with cabergoline and underwent gamma knife radiosurgery. Among the patients in the paradoxical immunoexpression group, 16 suffered tumor progression. Four patients underwent further surgery, seven patients were treated with gamma knife radiosurgery, and one patient received fractionated irradiation. None of the eight patients who were treated with gamma knife radiosurgery and fractionated irradiation showed further tumor progression. Four patients in this group were treated with cabergoline, but they all suffered further tumor progression and underwent additional salvage treatments.

CONCLUSIONS

Out of the pituitary differentiation lineage, paradoxical hormonal expression occurred in three-quarters of the patients identified. Further surgery or gamma knife radiosurgery should be given priority in times of tumor progression because most patients were resistant to dopamine agonists.

摘要

目的

本研究旨在阐明无高泌乳素血症的泌乳素分泌型垂体腺瘤的发生率,并确定这些肿瘤的适当治疗策略。

方法

本回顾性分析聚焦于无高泌乳素血症的泌乳素分泌型腺瘤,这些腺瘤最初被作为无功能垂体腺瘤通过手术进行治疗。在 942 例经组织学证实的垂体腺瘤患者中,我们于 2005 年 4 月至 2019 年 3 月间发现 114 例(12.1%)无高泌乳素血症的泌乳素分泌型腺瘤患者,其中包括 68 例男性和 46 例女性。

结果

在确定的 114 例患者中,13 例(11.4%)为单纯泌乳素表达,18 例(15.8%)为 pit-1 谱系激素表达,83 例(72.8%)为除泌乳素以外的垂体分化谱系的反常免疫表达。在随访期间,有 19 例患者肿瘤进展,其中 14 例需要挽救治疗。19 例患者中,11 例接受了伽玛刀放射外科治疗,均未发生进一步肿瘤进展。给予卡麦角林治疗 6 例,其中 1 例肿瘤缩小。然而,另外 5 例接受卡麦角林治疗的患者肿瘤进一步进展,需要另一种挽救治疗。在单纯泌乳素表达组中,有 1 例患者肿瘤复发,接受了伽玛刀放射外科治疗。在 pit-1 谱系组中,有 2 例患者肿瘤复发。1 例患者接受卡麦角林治疗后肿瘤进一步进展,再次接受伽玛刀放射外科治疗。在反常免疫表达组中,有 16 例患者肿瘤进展。4 例患者进一步手术,7 例患者接受伽玛刀放射外科治疗,1 例患者接受分次照射。8 例接受伽玛刀放射外科和分次照射治疗的患者均未发生进一步肿瘤进展。该组中有 4 例患者接受卡麦角林治疗,但均出现肿瘤进一步进展,需要进行额外的挽救治疗。

结论

除泌乳素以外的垂体分化谱系的反常激素表达在确定的患者中占四分之三。在肿瘤进展时,应优先考虑进一步手术或伽玛刀放射外科治疗,因为大多数患者对多巴胺激动剂耐药。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验